51.47
+0.26(+0.51%)
Currency In USD
| Previous Close | 51.21 |
| Open | 51.08 |
| Day High | 51.48 |
| Day Low | 49.94 |
| 52-Week High | 54.6 |
| 52-Week Low | 21.72 |
| Volume | 1.21M |
| Average Volume | 2.86M |
| Market Cap | 9.84B |
| PE | -12.46 |
| EPS | -4.13 |
| Moving Average 50 Days | 48.39 |
| Moving Average 200 Days | 37.47 |
| Change | 0.26 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,868.24 as of September 15, 2025 at a share price of $51.47. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,391.46 as of September 15, 2025 at a share price of $51.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
GlobeNewswire Inc.
Sep 06, 2025 6:30 PM GMT
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseli
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webin
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
GlobeNewswire Inc.
Sep 02, 2025 11:30 AM GMT
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 da